All About Multiple Sclerosis

More MS news articles for October 2002

Serum levels of sTNFR-1 and sFas in patients with relapsing-remitting multiple sclerosis

Med Sci Monit 2002 Oct;8(10):CR720-3
Bilinska M, Frydecka I, Podemski R, Gruszka E.
Clinic of Neurology, Medical University of Wroclaw, Poland.


During the relapse of multiple sclerosis (MS), activated T cells, T cells autoreactive against myelin antigens as well as antigen-nonspecific lymphocytes and monocytes produce a number of proinflammatory cytokines such as TNF (Tumor Necrosis Factor). For a proinflammatory effect to take place TNF must bind together with appropriate receptors. The aim of the study was to assess value of serum sTNFR-1 and sFas levels with reference to clinical activation of disease.


The absence of changes in serum sTNFR-1 levels relative to clinical activation of the disease makes this measurement ineffective in the assessment of MS status. On the other hand, the measurement of serum sFas levels may be a valuable parameter for the monitoring of both MS clinical course and immune response to treatment when the symptoms of neurological deficit aggravate.